Maintenance of T-cell function and modulation of tolerance are critical issues in organ transplantation. The thymus is the primary organ for T-cell generation, and a preserved thymic function is essential for a selftolerant diverse T-cell repertoire. Transplant procedures and related immunosuppressive drugs may hinder thymic integrity and function. We review here the recent advances in understanding the regulation of the unique thymic microenvironment with relevance for the field of transplantation.
INTRODUCTION
The thymus is the primary organ for T-cell development, in which a T-cell repertoire able to recognize foreign antigens, yet tolerant to self, is generated early in life [1] . The contribution of the thymus to T-cell homeostasis after the first years of life was neglected for many years because of the acknowledged age-dependent thymic involution [2] [3] [4] . However, there is now clear data supporting lifelong thymic activity, posing the thymus as a fundamental target for the replenishment of the T-cell compartment [5, 6] . The thymus is sometimes removed in part or whole for cardiac or lung transplantation, raising concerns about the lifelong impact of thymectomy [7] [8] [9] . Organ transplantation is usually associated with the use of immunosuppressive therapies that hinder the thymus. Residual thymic function and thymic regeneration might be key to re-establish host defense [10] . Deliberate thymus manipulation by direct or peripheral injection of antigen or cells might be used to generate allogeneic tolerance [11] . Finally, the thymus itself is sometimes transplanted, either to establish immunity [12] or to generate tolerance [13] . Recent findings set the scene for promising strategies to be used in clinical settings of organ transplantation to ensure immune reconstitution upon immunosuppressive interventions and to modulate T-cell tolerance ( Fig. 1 ).
THYMUS TRANSPLANTATION
Hematopoietic precursors originated in the bone marrow enter the thymus through the corticomedullary junction and must proceed through a series of stages to become mature, functional T cells. These stages are characterized by the expression of CD4 and CD8, as well as CD3, at the surface of thymocytes, with the different stages of T-cell development being differentially located in the thymus: immature double-positive (CD4 þ CD8 þ ) cells are found in the cortex, whereas more mature CD4 single-positive (CD4SP, CD4 þ CD8 neg CD3 high ) and
CD8 single-positive (CD8SP, CD4 neg CD8 þ CD3 high ) cells are located in the medulla [14] .
Thymocyte differentiation is dependent on the interaction of developing thymocytes with other cells, particularly thymic epithelial cells (TECs) and dendritic cells, in order to ensure that the T cells produced are able to recognize self-MHC (positive selection, mainly mediated by cortical TECs) but do not become activated upon self-antigen presentation (negative selection, mediated by dendritic cells and medullary TECs) [15, 16] .
Defects in thymic development, like DiGeorge syndrome, or mutations in the genes essential for TEC differentiation, such as Forkhead box N1 (FOXN1), may result in athymia, defined by less than 1% naïve T cells in the blood [17, 18] . These cases of severe immunodeficiency can only be treated with thymus transplantation. Thymic transplantation, previously applied in the treatment of complete DiGeorge anomaly in infancy [12, 19] , has been successfully used for the first time in the context of another clinical setting characterized by putative athymia, FOXN1 deficiency [20,21 & ]. Importantly, functional immune competence was obtained using an HLA-mismatched thymus and was sustained despite the evidence of allograft involution 3 years after thymus transplantation [21 & ]. These findings suggest that a transitory period of thymic activity is sufficient to ensure the establishment of a functional immune system. Furthermore, they provide new insights for the design of immunological reconstitution strategies based on thymic transplantation, including xenotransplantation [22] . Additionally, the potential of the conjoint use of thymus transplantation with hematopoietic stem cell transplantation (HSCT) to facilitate
KEY POINTS
The central role of the thymus in the establishment of the T-cell-receptor repertoire and tolerance disclose a potential in organ transplantation that is beginning to be explored. IL-22 was recently revealed as a major pathway underlying the unique ability of the thymus to regenerate.
Critical molecular mechanisms that regulate the function of the thymic epithelia were uncovered, which may translate into advances in the modulation of the thymic microenvironment, as well as in the generation of a putative artificial thymus.
The thymus was shown to have the ability to sustain thymocyte progenitor renewal.
The human phenotype of FOXN1 deficiency, a key molecule for thymic epithelium development and function, and its recovery upon thymic transplantation were comprehensively characterized. long-term immune reconstitution in the context of severe combined immunodeficiencies (SCIDs) is also an area of research [23] .
MANIPULATION OF THYMIC ACTIVITY IN THE CONTEXT OF SOLID-ORGAN TRANSPLANTATION
There is increasing evidence supporting that a normal thymus is able to export mature T cells throughout life, although with a progressive decline with age [5, 6] . Nevertheless, the current tools available to accurately estimate the diversity and function of the T cells that emigrate from the thymus are limited. Furthermore, the mechanisms underlying the thymic changes throughout life, including the relative contribution of putative impairments of precursor cells and of the thymic microenvironment, remain unclear. The progressive decline of thymic function with age is considered an important factor in limiting the success of bone marrow transplantation in the elderly [24, 25] . Strategies to recover thymic function and to ensure the replenishment of the peripheral compartment with a pool of newly generated diverse T cells are particularly crucial in situations that may lead to T-cell depletion, such as immunosuppressive therapies, radiation/chemotherapy and HIV infection. The thymic epithelium is particularly susceptible to the deleterious effects of stress, inflammation, infections and immunosuppressive drugs, leading to impaired thymopoiesis [26] . Understanding the mechanisms underlying the preservation and recovery of the thymic microenvironment is of paramount importance for its therapeutic targeting.
IL-22 AS A NOVEL PLAYER IN THYMIC EPITHELIUM RECOVERY
Interleukin-22 (IL-22) has been suggested to have a fundamental role in tissue homeostasis and repair [27] . It is produced by subsets of CD4 T cells and of innate lymphoid cells (ILCs), and mainly targets epithelial cells. IL-22 was recently identified as an important player in thymic regeneration [28 && ,29] . Dudakov et al. found that IL-22-deficient mice presented impaired thymic regeneration upon sublethal total body irradiation and were unable to reconstitute thymic cellularity upon subsequent HSCT. Moreover, IL-22 production increased upon thymic insult in wild-type mice. IL-22 appeared to be mainly produced by thymic ILCs in response to tissue damage, and this process was at least partly regulated by dendritic cells through the production of IL-23. The receptor for IL-22 was shown to be expressed on TECs and to induce their survival and proliferation. This direct impact of IL-22 on TECs may have many potential applications.
FINE-TUNING OF THYMIC EPITHELIUM FUNCTION BY MICRORNAS
Thymic involution is mediated by a variety of factors such as sex hormones, physiological stress, inflammation and infection, but the mechanisms underlying the action of each factor are not completely understood. Recently, microRNAs (miRNAs) have been found to be essential in maintaining the competence of the thymic epithelia in the mouse [30 && ,31 && ]. This class of small noncoding RNAs controls the cellular RNA machinery by targeting and downregulating the expression of mRNAs [32] . Dicer is an RNAse III critical for miRNA generation by catalyzing miRNA duplex formation [33] . Papadopoulou et al. [30 && ] have found that TEC-specific deletion of Dicer resulted in the degeneration of thymic architecture and function, inducing heightened sensitivity to involution signals. Furthermore, targeted deletion of the miR-29a cluster recapitulated premature thymic involution and hypersensitivity to pathogenassociated signals found in the absence of Dicer, revealing this particular miRNA family as a key modulator of the threshold of thymic epithelium responses to pathogens.
In another study, Zuklys et al. [31 && ] also found that T cells generated in a miRNA-free TEC environment elicited autoimmunity, possibly because of the reduction of the expression of self-antigens in medullary TECs, leading to an impaired control of autoreactive T cells in the thymus.
Overall, a major role for miRNAs in thymic epithelium function and maintenance was revealed, raising new perspectives for therapeutic intervention.
IDENTIFYING THE MOLECULAR REQUIREMENTS FOR THE CROSS-TALK BETWEEN THYMIC EPITHELIAL CELLS AND THYMOCYTES
The identification of the requirements for T-cell commitment and development has been the subject of extensive research. Caldéron and Boehm have recently revealed a hierarchy of molecular cues that governs the differentiation of hematopoietic progenitors in the enlarged murine thymus [34 && ,35 ]. In their model, the chemokines CCL25 and CXCL12, the cytokine stem cell factor (Scf) and the Notch ligand delta-like 4 (DLL4), not expressed in Foxn1deficient epithelia, were placed under the regulation of the Foxn1 promoter in Foxn1-deficient mice. Foxn1 is a transcription factor crucial for thymic epithelium development and prevention of its involution [36, 37] . Whereas the expression of CCL5, CXCL12 or Scf was sufficient for hematopoietic progenitor cells to be detectable, although at very low levels, DLL4 alone did not induce hematopoietic activity. However, through the combinatorial expression of the four molecules, the authors uncovered the determinants of the microenvironmental niche required for T-cell development. According to their results, CCL25 was positioned at the bottom of the functional hierarchy, whereas DLL4 had a dominant T-cell-promoting function over the other molecules studied. In the absence of Notch function, CXCL12 was found to promote B-cell development, whereas Scf appeared to generate a favorable environment for mast cell progenitors. Importantly, the combined expression of CXCL12 and DLL4 in Foxn1-deficient epithelia was sufficient to support T-cell development up to the double-positive stage, probably because of the chemotactic activity of CXCL12, lacked by DLL4. Moreover, these double-positive T cells were able to differentiate into mature CD4SP and CD8SP cells in the presence of wild-type thymic epithelium in reaggregate thymus organ culture, suggesting that interruption of thymopoiesis at that stage was because of the lack of critical extracellular signals in Foxn1-deficient epithelia.
These results are of paramount importance for the manipulation of hematopoietic progenitor niches, with potential clinical applications.
THE HUMAN PHENOTYPE OF FOXN1 DEFICIENCY AND ITS RECOVERY BY THYMIC TRANSPLANTATION
We and others have shown that children with a homozygous FOXN1 mutation (R255X) feature T cells of nonmaternal origin, despite the athymia [18,20,21 & ]. The circulating T cells present an activated memory-like phenotype, impaired function and an oligoclonal repertoire, with an aberrant overrepresentation of CD4 neg CD8 neg double-negative and of Forkhead box P3 (FOXP3) regulatory-like ab T cells [21 & ]. Several possibilities may be raised to explain their origin. A thymic origin of circulating T cells in human FOXN1 deficiency cannot be excluded. It is plausible that the FOXN1 mutation allowed the development of a thymic rudiment able to support altered thymopoiesis, with possible disturbances in positive or negative selection, as suggested by the double-negative and FOXP3 þ cell expansions. On the other hand, an extrathymic origin should also be considered, although the possibility of T-cell development in lymph nodes and gut has been subject of intense debate and controversial data [38, 39] . In this respect, two recent reports should be considered, which describe the potential of human tonsils to support T-cell development [40 & ] and the possible contribution of mesenteric lymph nodes for the extrathymic development of murine T cells upon administration of bone marrow progenitors [41 & ].
REVEALING THE THYMIC ABILITY TO SUSTAIN THYMOPOIESIS IN THE ABSENCE OF PROGENITOR INPUT
It was long believed that the thymus was entirely dependent on the inner traffic of progenitor cells from the bone marrow. This notion derived from the observation that transplantation of wild-type thymus grafts into T-cell-deficient mice resulted in the export of a single wave of graft-derived T cells, and that colonization of the graft by developmentally impaired progenitors from the bone marrow resulted in cessation of T-cell production [42, 43] .
Peaudecerf et al. [44 && ] and Martins et al. [45 && ] revisited this dogma, showing in mouse models that the thymus harbors progenitors with self-renewal potential that are able to maintain T-cell development in the absence of competition from bone marrow progenitors. These recent studies unveil a mechanism of regulation of normal thymocyte development by niche occupancy and competitive progenitor replacement.
Overall, these studies highlight the capacity of the thymus to support cells with long-term renewal potential.
INTRATHYMIC INJECTION OF THYMOCYTE PROGENITORS
The intrathymic delivery of thymocyte progenitors has been investigated as a strategy to reduce the delay in immune reconstitution following HSCT, a main cause of the associated morbidity and mortality. Recent studies from De Barros et al.
] in murine models showed that, in the absence of myeloablative conditioning, the forced thymic entry of semiallogeneic progenitors results in sustained T-cell development, even across histocompatibility barriers.
MODULATING T-CELL RESPONSES AT THE THYMIC LEVEL
Another important area of thymic intervention relates to the role of the thymus in the establishment of the T-cell-receptor repertoire. Much effort has been devoted into developing ways to achieve hematopoietic chimerism for the purpose of generating central tolerance [11] . Moreover, the development of strategies to induce tolerance through the direct introduction of antigens in the thymus has been a long pursued goal in the field of transplantation [47, 48] . Several approaches have been attempted to modulate specific T-cell responses, including the intrathymic injection of antigens using lentiviral vectors as recently reported by Gottrand et al. [49 & ]. On the other hand, although the thymus is generally considered an immune-privileged organ, increasing evidence points to a recirculation of mature T cells and antigen-presenting cells through the thymus, with possible modulation of peripheral effector and regulatory T-cell responses [50] . The majority of the studies addressing this issue has been conducted in mouse models of infection, such as the recently published work of Nobrega et al.
[51 & ] with mycobacteria. This field of research has an immense translational potential in the context of organ transplantation to induce tolerance. In this regard, we have recently identified the double-positive stage of thymocyte development as a potential target for the modulation of thymic-derived FOXP3 þ regulatory T cells [52 & ]. These findings illustrate an early generation of this important subset for T-cell homeostasis and self-tolerance, with critical implications for the diversity and autoreactivity of the natural Tregcell repertoire.
CONCLUSION
The thymus has recently emerged as a promissory target for therapeutic intervention in the field of organ transplantation. Its unique regenerative potential and the identification of new key pathways involved raise the prospects to modulate or rebuild the patient's immune system. These advances in the comprehension of the thymic microenvironment regulation will be instrumental for therapeutic interventions in the endogenous thymus, thymic transplantation, and future development of artificial thymus, which would represent an important tool to achieve tolerance across histocompatibility barriers.
